Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEADLIGHT: Hypofractionated Proton Therapy for Head and Neck Cancers
NCT05075980Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Feb 2022
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck carcinoma (HNC) (3 arms), sponsored by Mayo Clinic. Primary endpoints: Rate of local/regional control at 2 years and MD Anderson Dysphagia Inventory score at 2 years. Started Feb 2022; status: active, not recruiting.
02
Conditions
head and neck carcinoma (HNC)
Beyond the preview
Go deeper on NCT05075980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075980.